WJFW

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...